Sectors
PVLA
Palvella Therapeutics, Inc.
142.88
1 x 141.35
1 x 142.49
bid
ask
-
1.06
0.73%
09:59 AM
timesize
| Ytd | 36.51% | |
| 1y | 296.90% |
140.75
day range
142.70
31.01
52 week range
161.38
| Open | 142.19 | Prev Close | 143.94 | Low | 140.75 | High | 142.70 | Mkt Cap | 1.70B |
| Vol | 17.93K | Avg Vol | 268.68K | EPS | -4.17 | P/E | -34.52 | Forward P/E | -22.15 |
| Beta | -0.20 | Short Ratio | 8.17 | Inst. Own | 96.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 125.57 | 200-d Avg | 106.59 | 1yr Est | 229.60 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-13 | 2026-06 | -1.16 | N/A | N/A | N/A |
| 2026-05-07 | 2026-03 | -0.9 | -1.2 | -0.3 | -33.33% |
| 2026-03-31 | 2025-12 | -0.91 | -1.08 | -0.17 | -18.53% |
| 2025-11-11 | 2025-09 | -0.85 | -1.03 | -0.18 | -21.18% |
| 2025-08-14 | 2025-06 | -0.78 | -0.86 | -0.08 | -10.26% |
| 2025-05-15 | 2025-03 | -3.4 | -0.74 | 2.66 | 78.24% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-21 | Stephens & Co. | Upgrade | Overweight | Overweight |
| 2026-05-21 | Chardan Capital | Upgrade | Buy | Buy |
| 2026-05-12 | Stephens & Co. | Upgrade | Overweight | |
| 2026-03-31 | Chardan Capital | Upgrade | Buy | Buy |
| 2026-03-24 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-03-16 | Chardan Capital | Upgrade | Buy | Buy |
Profile
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-08-11 | ADAR1 CAPITAL MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2026-06-16 | GOIN KATHLEEN | Chief Operating Officer | 0.00 | Sale |
| 2026-02-26 | HERON ELAINE J | Director | 53.69K | Purchase |
| 2026-03-29 | JENKINS GEORGE M | Director | 201.13K | Purchase |
| 2026-06-11 | KORENBERG MATTHEW E | Chief Financial Officer | 1000 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Suvretta Capital Management, LLC | 1.15M | 0.00 | 8.05% |
| 2026-03-30 | First Light Asset Management, LLC | 980.76K | 0.00 | 6.85% |
| 2026-03-30 | Bvf Inc | 960.99K | 0.00 | 6.71% |
| 2026-03-30 | Frazier Life Sciences Management, L.P. | 882.40K | 0.00 | 6.16% |
| 2026-03-30 | BlackRock Inc | 686.85K | 0.00 | 4.80% |
| 2026-03-30 | Jennison Associates LLC | 640.61K | 0.00 | 4.47% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | State Street® SPDR® S&P® Biotech ETF | 407.17K | 0.00 | 2.84% |
| 2026-06-29 | Vanguard Total Stock Mkt Idx Inv | 388.39K | 0.00 | 2.71% |
| 2026-06-29 | iShares Russell 2000 ETF | 283.27K | 0.00 | 1.98% |
| 2026-03-30 | Federated Hermes Kaufmann R | 276.56K | 0.00 | 1.93% |
| 2026-03-30 | Federated Hermes Kaufmann Growth | 276.56K | 0.00 | 1.93% |
| 2026-03-30 | Eventide Healthcare & Life Sciences I | 231.48K | 0.00 | 1.62% |